Dermatology

The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.

Latest News

Hidradenitis suppurativa. | Image Credit: syahrir - stock.adobe.com
Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

July 2nd 2025

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.

UV Safety Awareness Month | Image Credit: Nass Studio - stock.adobe.com
Sun Exposure Risks Brought to Light During UV Safety Awareness Month

July 1st 2025

FDA approval. | Image Credit: aznan - stock.adobe.com
FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid

June 20th 2025

Prurigo Nodularis. | Image Credit: this_baker - stock.adobe.com
Nemolizumab’s Long-Term Data Reinforce Efficacy, Tolerability in Prurigo Nodularis

June 19th 2025

Ruxolitinib cream. | Image Credit: Ladanifer - stock.adobe.com
Topical Ruxolitinib Emerges as Promising Therapy for Diverse Inflammatory Skin Conditions

June 17th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives
Continuing Medical Education
View All
July 4th 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
July 4th 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology
July 4th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 4th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
March 15th 2024

Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients With Plaque Psoriasis

Pearl Steinzor
Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh, shares 16-week safety and efficacy data from the FRONTIER 2 clinical trial on JNJ-2113 for patients with moderate to severe plaque psoriasis.
Martin Dahl, PhD, senior vice president, AnaptysBio
March 11th 2024

Dr Martin Dahl Discusses the Pathophysiology of AD and Benefits of ANB032

Pearl Steinzor
AnaptysBio's senior vice president of research, Martin Dahl, PhD, discusses therapeutic strategies and pathophysiological approaches to treating patients with atopic dermatitis (AD).
Jeff Stark, MD, vice president, head of medical immunology, UCB.
March 11th 2024

Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS

Pearl Steinzor
Jeff Stark, MD, vice president and head of medical immunology, UCB, shares phase 3 study results of bimekizumab-bkzx given for up to 48 weeks in patients with moderate to severe hidradenitis suppurativa (HS).
Books with stethoscope | Image credit: ronstik - stock.adobe.com
March 11th 2024

Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

Julia Bonavitacola
Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.
Hands with atopic dermatitis | Image credit: InfiniteStudio - stock.adobe.com
March 11th 2024

Biologic, Topical Therapies Both Effective in Treating AD in Skin of Color

Julia Bonavitacola
Presented posters showed that moderate to severe atopic dermatitis (AD) in skin of color can be treated with either biologic or topical therapies.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
March 10th 2024

Dr Jonathan Silverberg Discusses Findings on the Safety, Efficacy of Nemolizumab at 48 Weeks

Pearl Steinzor
In patients with moderate to severe atopic dermatitis, nemolizumab demonstrated good durability of response, explained Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences.
Woman with hidradenitis suppurativa under arm | Image credit: Lea - stock.adobe.com
March 10th 2024

Management of HS Requires Both Coordination, Communication Between Patients and Providers

Julia Bonavitacola
Treating pediatric and adult patients with hidradenitis suppurativa (HS) who are in socioeconomically underserved areas can be done through collaboration with the patient, their family, and other clinicians in the field.
Vitiligo in light skin | Image credit: shurkin_son - stock.adobe.com
March 10th 2024

Skin Tone Bias Persists in Google Searches for Vitiligo

Julia Bonavitacola
Pictures of darker skin with vitiligo make up more than three-quarters of Google searches for pictures of vitiligo, according to posters.
Monica Li, MD, University of British Columbia
March 10th 2024

Dr Monica Li Discusses Tailoring Microneedling Treatments to Meet Each Patient's Need

Pearl Steinzor
Monica Li, MD, medical and cosmetic dermatologist and clinical assistant professor, University of British Columbia, discusses how microneedling can address both aesthetic and medical dermatological needs across different skin types.
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
March 9th 2024

Dr Robert Sidbury: Understanding What Makes a Dermatology Practice Successful

Pearl Steinzor
Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses what makes a dermatology practice successful and the challenges that come with running a practice.
Older adult with atopic dermatitis | Image credit: berna_namoglu - stock.adobe.com
March 9th 2024

Atopic Dermatitis in Adults: Challenges and Treatment Strategies

Julia Bonavitacola
A session held at the American Academy of Dermatology Annual Meeting 2024 highlighted the ways in which atopic dermatitis can be treated and addressed in adults and older adults.
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
March 8th 2024

Dr Raj Chovatiya Outlines Who Is a Good Candidate for Oral JAK Inhibitors

Pearl Steinzor
There are key factors to consider when selecting which patients with atopic dermatitis (AD) are suitable candidates for oral Janus kinase (JAK) inhibitors, explained Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research.
Man applying cream to rash | Image credit: Olga - stock.adobe.com
March 8th 2024

Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments

Julia Bonavitacola
A physician-reported outcomes survey found that physicians switched to ruxolitinib cream due to lack of effectiveness with previous atopic dermatitis (AD) treatments, and an analysis of claims data revealed the cream reduced the need for other treatments.
FDA Approved - chrisdorney - stock.adobe.com
February 16th 2024

FDA Grants Accelerated Approval to Lifileucel, First Cellular Therapy for Advanced Melanoma

Rose McNulty
Lifileucel was granted approval for the treatment of adults with unresectable or metastatic melanoma that has been previously treated with other therapies, marking the first approval of a tumor-derived cellular therapy in a solid tumor cancer.
ICYMI: Highlights From Fall Clinical Dermatology Conference 2023
January 2nd 2024

ICYMI: Highlights From Fall Clinical Dermatology Conference 2023

Cameron Santoro
The 2023 Fall Clinical Dermatology conference featured research on treatments for alopecia areata, acne, psoriasis, atopic dermatitis, and vitiligo.
Top 5 Most-Read Dermatology Content of 2023
December 28th 2023

Top 5 Most-Read Dermatology Content of 2023

Cameron Santoro
The top 5 most-read dermatology content of 2023 included topics in melanoma, acne scarring, hidradenitis suppurativa, chronic kidney disease, hyperhidrosis, and infertility rates.
Sun block on arm | Image Credit: bertys30 - stock.adobe.com
December 27th 2023

Examining Skin Cancer Beliefs and Behaviors Among Hispanic People in Florida, Puerto Rico

Cameron Santoro
A study found Hispanic people in Tampa, Florida and Ponce, Puerto Rico are prone to sunburns but lack sun safety habits, putting them at higher risk for skin cancer.
FDA Approval Illustration | Image Credit: bakhtiarzein - stock.adobe.com
December 18th 2023

FDA Approves Tralokinumab for Adolescents With Atopic Dermatitis

Cameron Santoro
The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old.
ICYMI: Highlights From AAD 2023
December 18th 2023

ICYMI: Highlights From AAD 2023

Cameron Santoro
The 2023 coverage of the annual meeting of the American Academy of Dermatology (AAD) included FDA approvals, new treatment methods, patient advocacy, and more.
what we're reading logo
December 15th 2023

What We’re Reading: Inflation Penalties; Melanoma Vaccine; Respiratory Vaccine Coverage

AJMC Staff
A vaccine is showing promising results in treating melanoma; the Biden administration will implement inflation penalties on dozens of drugmakers to reduce out-of-pocket costs for Medicare recipients; the CDC issued an alert urging health care providers to increase immunization coverage for influenza, COVID-19, and respiratory syncytial virus (RSV).
Hidradenitis Suppurative | Image Credit: Yurii Kibalnik - stock.adobe.com
December 12th 2023

How Diet Is Related to Hidradenitis Suppurativa Symptoms

Cameron Santoro
Hidradenitis suppurativa can either worsen or benefit depending on various dietary influences, either included, or excluded by the patient.
AI application scanning mole | Image Credit: Taras Grebinets - stock.adobe.com
December 7th 2023

Review Examines Pros and Cons in AI Detection of Skin Cancer

Cameron Santoro
Utilizing artificial intelligence (AI) to diagnose skin cancer raises concerns around the level of accuracy it delivers consumers, health care professionals, and other dermatology experts.
Vitiligo Depigmentation | Image Credit: Vikky Mir - stock.adobe.com
December 5th 2023

Vitamin D Analogues Combined With Topical Corticosteroids Successfully Treats Vitiligo

Cameron Santoro
Patients with vitiligo can increase repigmentation through vitamin D and topical corticosteroid therapy.
Doctor performing a check for skin cancer | Image credit: InsideCreativeHouse - stock.adobe.com
November 24th 2023

Neoadjuvant Cemiplimab in CSCC Can Reduce Treatment Burden in Adjuvant Setting, Says Dr Neil D. Gross

Laura Joszt, MA
Neoadjuvant cemiplimab followed by surgery resulted in favorable survival outcomes for patients with resectable stage II to IV cutaneous squamous cell carcinoma (CSCC), addressing an area of unmet need, explained Neil D. Gross, MD, FACS, of MD Anderson.
Black patient speaking with doctor | Image credit: Seventyfour - stock.adobe.com
November 19th 2023

Navigator Program Improves Continuity of Care for Patients With Skin of Color

Laura Joszt, MA
Patients with diverse skin types can experience diagnostic delays, access to care issues, and quality-of-life burdens that a navigator program may be able to help alleviate.
Urticaria symptoms | Image credit: suriya - stock.adobe.com
November 15th 2023

Remibrutinib Shows Promise for Chronic Spontaneous Urticaria in Phase 3 Trials

Rose McNulty
Remibrutinib, an investigational, highly selective Bruton tyrosine kinase inhibitor, showed favorable results in the treatment of chronic spontaneous urticaria (CSU) in as early as 2 weeks in the phase 3 REMIX-1 and REMIX-2 studies.
Stethoscope on pride flag | Image credit: manassanant - stock.adobe.com
November 9th 2023

Dermatologists Play Crucial Role in Support and Inclusivity of Transgender and Gender-Diverse Patients

Emma Andrus
Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.
dr peter lio
November 7th 2023

Dr Peter Lio Lists Dermatology Treatment Barriers

Brooke McCormick Hayden E. Klein
Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, lists barriers to care for dermatology patients.
Red FDA approved stamp
October 31st 2023

Secukinumab Gains FDA Approval to Treat Hidradenitis Suppurativa

Laura Joszt, MA
The approval of secukinumab is the second approved biologic to treat hidradenitis suppurativa.
Group of diverse women | Image credit: Anna Shvets - pexels.com
October 23rd 2023

Darker Skin Means Different Presentations of Skin Diseases, Explains Dr James Song

Hayden E. Klein
Recognizing that skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa present differently in skin of color can prevent delays in diagnosis and treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.
<12345678
...
11>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo